Novartis announced a strategic collaboration with Atropos Health to use AI for streamlining the identification of undiagnosed rare disease patients, aiming to reduce time to diagnosis and treatment. The company will also present new cardiovascular data at an upcoming conference, highlighting the strength of its portfolio, including studies on Leqvio, pelacarsen, and Entresto for various heart conditions.